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Background: Refusal of heterogenic blood products can be for religious reasons as in Jehovah's Witnesses or
otherwise or as requested by an increasing number of patients. Furthermore blood reserves are under continuous
demand with increasing costs. Therefore, transfusion avoidance strategies are desirable. We describe a historic
comparison and current results of blood saving protocols in Jehovah's Witnesses patients.
Methods: Data on 250 Jehovah’s Witness patients operated upon between 1991 and 2003 (group A) were
reviewed and compared with a second population of 250 patients treated from 2003 to 2012 (group B).
Results: In group A, mean age was 51 years of age compared to 68 years in group B. An iterative procedure was
performed in 13% of patients in group B. Thirty days mortality was 3% in group A and 1% in group B despite
greater operative risk factors, with more redo, and lower ejection fraction in group B. Several factors contributed to
the low morbidity-mortality in group B, namely: preoperative erythropoietin to attain a minimal hemoglobin value
of 14 g/dl, warm blood cardioplegia, the implementation of the Cornell University protocol and fast track
extubation.
Conclusions: Cardiac surgery without transfusion in high-risk patients such as Jehovah Witnesses can be carried
out with results equivalent to those of low risk patients. Recent advances in surgical techniques and blood
conservation protocols are main contributing factors.Background
Patients undergoing cardiac surgery receive blood trans-
fusion in 20-80% of cases. Certain studies suggest that
half of these transfusions are unnecessary and can be
avoided [1,2]. Furthermore, multivariate analyses have
identified blood transfusion as an independent factor for
mortality in the long term. Patients and their kin,
informed of the feasibility of surgery without blood
transfusion have frequently opted for this choice. On the
other hand the need for blood products is on the rise
due to the aging demographic of the population, a re-
duction in the number of potential donors and an in-
crease in the costs of transfusions due to increased
vigilance over the quality of blood and more stringent
sanitary measures [3,4].* Correspondence: claudevaislic@hotmail.com
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reproduction in any medium, provided the orOver the course of the last 21 years, we have performed
cardiac surgery on 500 patients of the Jehovah witness
faith which requires its followers to refrain from blood
transfusions. In all of these cases, no transfusion was per-
formed. Over this period, the techniques of blood preser-
vation have improved greatly and have become rather
systematized, together with an overall improvement in the
operative risk of cardiac surgery. In order to measure the
effects of advances in blood conservation techniques, we
compared our first 250 Jehovah Witness cases to a subse-
quent group of 250 patients, paying particular attention to
the impact of the introduction of preoperative erythropoi-
etin (EPO) in the latter group.Methods
Between January 1991 and January 2012 , elective car-
diac surgery was performed on 500 Jehovah’s Witnesstd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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phasis on the risks of non-transfusion. During this
period, 622 patients were referred to our team and 122
were excluded (Table 1). Until 1998, 37 patients were
excluded because their hemoglobin level was below
14 g/l, which was no longer the case afterwards due to
the systematic use of Erythropoietin. Consultation with
local ethics committee established inclusion and exclu-
sion criteria, thus we excluded emergency procedures,
congenital heart disease, cardiogenic shock, patients in
whom a prolonged EPO treatment did not produce a
hemoglobin level of 14 g, patients with problems of
hemostasis or those in whom coagulopathy was antici-
pated following the implementation of extra-corporal
circulation (cold agglutinin coagulopathy, sickle cell dis-
ease) and patients with thoraco-abdominal aneurysms in
which we could not reasonably avoid transfusion. Three
patients suffering from aortic dissection were excluded
due to initial preoperative hemoglobin levels below 15 g/
l. Three patients could not be operated upon due to it
being impossible to attain sufficient levels of hemoglobin
prior to the scheduled procedure, despite a month of
EPO treatment. One of these patients showed signs of
an increase in the size of a type 1 aortic dissection which
became chronic following his refusal of a transfusion
despite the advice of the care team. The other patient
could not be operated upon due to a reaction to EPO of
unidentifiable cause.
The method of blood conservation utilized over the
years has evolved, resulting in the adoption of the “Com-
prehensive Multimodality Blood Conservation Program”
developed by Cornell University, detailed on Table 2 [5,6].
Aprotinin and EPO were used as dictated by protocol
(Table 3). Aprotinin, which enhances erythrocyte
hematopoiesis was used in all our patients according to
Hammersmith Hospital protocol until its withdrawal in
2007 , then aminocaproic acid is used in all cases . Prior
to 1998, all patients with hemoglobin levels below 14 g/l
were refused. After 1998, EPO was used systematically in
all our patients with hemoglobin levels below 14 g/l priorTable 1 Exclusion Criteria
n
Hemoglobin < 14 g/l prior to 1998 37
Emergency Procedures 36
Complex Congenital Heart Disease 5
Cardiogenic Shock 10
Ineffective EPO therapy 3
Sickle cell disease 1
Non correctable hemostasis abnormality (low platelet count)
Body Mass Index < 15 7
Thoraco-abdominal aneurysm 16to surgical intervention. The issue of cost did not arise as
a factor as this medication was paid for by the patients.
The relatively high level of hemoglobin was intended to
extend the safety margin in these patients in whom post-
operative transfusion was not an option.
Elective cardiac catherization was done a few weeks
before surgery to avoid drops in hb and recently use of a
vascular closure device has been systematized.
As preoperative antiplatelet therapy is an identified
risk factor of bleeding requiring excess transfusion , we
discontinued clopidogrel and aspirin in all cases prior to
surgery (35 patients in group B). Aspirin alone was dis-
continued as well. 15 patients in group B had drug elut-
ing stents implanted and surgery was postponed until
three months later in order to be able to effectively dis-
continue all antiplatelet agent according to our protocol.
In January 2000, our therapeutic procedures for coron-
ary and valve surgery were enriched by the implementa-
tion of mini-extracorporal circulation with retropriming.
This consists of a centrifugal pump in a closed circuit.
The circuit is filled with the blood of the patient which
is drained passively through a venous canula, thus elim-
inating the crystalloid solutions which refill the circuit
and result in hemodilution.
We compared the operative risk, as measured by Euro-
score, as well as mortality, morbidity, hemoglobin levels
and blood loss in the first 250 cases, operated upon prior to
2003 (group A), to 250 patients operated upon thereafter
(group B). Moreover, due to the fact that the patients in
group B were at greater risk than those in group A, we also
verified that we were able to obtain results which were
nearly equivalent. The first objective was to compare the
mortality rates of the first 30 days following operation and
the incidence of postoperative blood loss in the two groups.
The second objective was to compare the clinical evolution
and hemoglobin levels throughout the hospital stay.
Statistical Analysis
The hypothesized normality of the distribution of con-
tinuous variables was verified by a Kolmogorov-Smirnoff
test. The continuous variables are expressed as means of
standard deviation and the differences were evaluated by
Student T test. Variable analysis was conducted by Chi-
Square and Fisher tests according to the size of the sam-
ple. Statistical significance was assumed when the P
value was found to be less than 0.05. Stataxt software
packages (Cytel Software Corporation, Cambridge,
Mass) were used in the statistical analysis.
Results
The type of operation, the mortality and the morbidity in
the first postoperative 30 days are shown in Tables 4 and
5. Significant technical developments and transfusion-
related risk factors are shown in Tables 6 and 2.
Table 2 Transfusion Related Risk Factors
Variable Group A n=250 Group B n=250 P
1991-1998 1998 - 2012
Blood Volume (ml) 5 200 +/- 480 5000 +/- 610 >0.05
Preoperative HCT (%) 41+/-2 40+/-4 <0.001
Preoperative erythrocyte mass (ml) 2215+/- 250 2010+/-200 < 0.05
Platelets 220 ± 60 180 ± 50 < 0 .05
Body Mass Index 25 ± 5 24 ± 3 >0.05
Age 51+/-7 68+/-5 <0.001
Female gender 11 28 <0.001
Diabetes 24 31 >0.05
Renal Failure 10% 10% >0.05
Euroscore 4.1 +/- 0.8 4.8 +/- 1.3 <0.05
Ejection Fraction 0.45+/-0.2 0.40+/-0.1 <0.001
Aortic Clamp Time 70+/-15 65+/-30 < 0.05
Ischemic Time 55+/-10 48+/-15 >0.05
Blood Loss (ml) 515 ± 310 350 ± 140 <0.001
Table 3 Protocols
1). Protocol for blood conservation a) Preoperative
EPO if hemoglobin levels are <14 g/l
Iron in all cases
Limit the removal of blood in frequency and quantity (use pediatric tubes)
Aprotinin (Hammersmith half-protocol)
Avoid hematomas following angiography and PCI.
b) Perioperative
Retropriming
Short CPB circuit. Heparinization 3 mg/kg body weight reversed by
equivalent dose of protamine IV
CPB conducted in normothermia (minimal temperature drift 36 °C)
Warm cardioplegia
Cell Saver
Minimally invasive surgical techniques
Meticulous closure
c) Post operative
Reduce blood retrieval in frequency and quantity (use pediatric tubes)
Reoperate if blood loss continues at 100 cc for three hrs, or immediately
if > 200 cc in one hour.
EPO if hematocrit < 24% at time of reoperation
2). Protocol of Aprotonin Administration
(Hammersmith Half-Protocol) until its
withdrawal in 2007 , then aminocaproic
acid is used in all cases
1 million KIU (140 mg) IV at induction of anesthesia, 1 million KIU (140 mg)
at completion of CPB and 250,000 KIU (35 mg) IV per hour until skin closure
or until a maximum dose of 1 million KIU.
3). Protocol of Erythropoietin Administration 300 UI/Kg IV + 500 UI/Kg subcutaneously on admission followed by 500 UI/Kg
subcutaneously every second day.
+ Iron 325 mg PO 3 times a day
4). Retropriming Avoid hemodilution during priming of CPB by passive drainage of blood
from venous system
5). MiniCPB CPB using centrifugal pump with small volume , in a closed circuit
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Table 5 Results
RESULTS Group A Group B P
30 Day Mortality 3 1 >0.05
Reoperation following bleeding 4 3 >0.05
Acute MI (tropoponine+ CPK MB) 2 1 >0.05
Mediastinitis 0 0 >0.05
Stroke 1 0 >0.05
Renal Failure (creatinine level > 2 mg/dL) 18 14 >0.05
Atrial Fibrillation 20 24 >0.05
Ultra-fast Track 0 77 < 0.001
ICU stay (Days) 3 +/-1 4 +/-1 >0.05
Mechanical Ventilation (hrs) 8 +/- 4 2 +/- 1 < 0.001
Hospitalization >7 days 32 18 < 0.001
CPK (creatinin phosphokinase), ICU (intensive care unit).
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of the circumstances of the procedure. All benefited from
treatment equivalent to what they would have received
had they not been Jehovah’s witnesses. This is particularly
true for the choice of valve substitute or conduit graft in
revascularization procedures which were again not influ-
enced by the fact that they were Jehovah’s witnesses.
The operative risk of these patients was assessed by a
passable Euroscore of 4.1 ± 0.8 to 4.9 ± 1.3 (p < 0.05) in
groups A and B respectively. In group B, we took into
account two aortic dissections and one adult congenital
heart disease, as well as patients who had previously
underwent cardiac surgery. In group B, although the
proportion of patients who were diabetic, female, or had
low ejection fractions increased, and the number of
patients over 70 years of age doubled, the incidence of
massive bleeding (defined as leading to hypovolemia or
shock) decreased.
Despite the increased risk associated with group B,
operative mortality diminished, due to progress in sur-
gical and medical techniques. We did not observe sig-
nificant renal failure, mediastinitis or enzymatic
increase indicative of myocardial suffering. Conversely
we did not observe stents occlusion in the patients
with drug eluting stents in whom antiplatelet therapy
has been discontinued. Thus, recently-operated patients
had a greater level of hemoglobin. The thoracic drain
output was halved (515 ml ± 31 vs 350 ml ± 140, in
groups A and B respectively) without major modifica-
tion or a more minimally invasive surgical technique,
as shown by the equivalent ischemic times. The peri-
operative hemoglobin and hematocrit levels were better
controlled in group B (Figures 1 and 2). 223/250 of theTable 4 Type of intervention from January 1991 to October 2
GROUP A
1991-2003
Intervention 30 days Morta
Aortic Valve Replacement 102 1
Mitral Valve Replacement 5
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VSD Repair LV Rupture
ASD (atrial septal defect), CABG (coronary artery bypass grafting), VSD (ventricular se
angioplasty.patients in group B were treated with preoperative
EPO due to insufficient hemoglobin levels (11 ± 2 g/l).
The four deaths were due to an ulceration of the gastro-
duodenal artery which could not be treated by endoscopic
sclerotherapy, renal failure and two hemorrhages which
occurred at the site of operation. Any bleeding greater
than 200 ml within the first 3 hours following surgery was
an indication for re-exploration which occurred in 4
patients in group A and 3 in group B.Discussion
1) Transfusion pro and con003
lity
ptal dAnaemia is a potent risk factor for mortality and
morbidity in surgical patients, and its managementGROUP B
2003-2012
30 days Mortality
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Table 6 Methods of Blood Conservation
Procedure Group A n=250 Group B n=250 P
1998-2003 2003-2012
Retro-priming 0 250 <0.001
Erythropoietin 0 203 <0.001
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transfusion in recent years.
Adverse effects of anaemia have been demonstrated
specifically in the perioperative setting. A
preoperative hemoglobin concentration of less than
6 g/dL increases the risk of death 30 days after
surgery by a factor of 26 relative to a concentration
of 12 g/dL or greater in surgical patients who
declined blood transfusion for religious reasons [7].
The safety of the blood supply has improved.
Sophisticated testing has led to a decline in the risk
of transfusion-related transmission of HIV, the
hepatitis C virus, and the hepatitis B virus.
But there is a continual rise in fatal TRALI
(transfusion-related acute lung injury) cases in the
United States from 2001 to 2006. TRALI occurred in
more than half of all transfusion-related fatalities
reported to the FDA in 2006, a higher number than
for any other single cause [8].
At the same time, there is evidence that
hemovigilance can reduce the risk of TRALI. TRALI
accounted for 6.8% of all transfusion-related adverse
events reported in the United Kingdom during the
period 1996–2003. This proportion declined to just
1.9% in 2006 [9].
Finally, despite the progress in screening blood for
HIV and the hepatitis viruses, some additional








ure 1 Additional file 1 is the HB comparison levels. Preo
ans preoperative. Posto means postoperative. Mi means
imum during bypass.blood supply safety. These include diseases newly
recognized as being transmissible by blood, for
which blood donor screening is not currently
available, or that are newly emergent infections for
which the potential for spread by transfusion is
unknown.
The Transfusion Requirement in Critical Care
(TRICC) trial was conducted in 838 critically ill
patients in intensive care settings. Patients were
randomized to a strategy of either liberal transfusion
(which begun when hemoglobin fell below 10 g/dL)
or restrictive transfusion (which begun when
hemoglobin fell below 7 g/dL). The restrictive
strategy was associated with significantly lower
mortality in two subgroups: patients with myocardial
infarction and patients with pulmonary edema.
Rao et al. performed a meta-analysis of three large
international trials of patients with acute coronary
syndromes to determine whether blood transfusion
to correct anaemia in this setting was associated with
improved survival [10]. They found significantly
higher mortality among patients who underwent
transfusion compared with those who did not,
prompting them to urge caution in the use of
transfusion to maintain arbitrary hematocrit levels in
stable patients with ischemic heart disease in an
observational cohort study of 11,963 patients who
underwent isolated coronary artery bypass graft
surgery, each unit of red blood cells transfused was
associated with an incrementally increased risk of
adverse outcome (eg, mortality, renal injury, need for
ventilator support, lengthened hospital stay,
infection) [11]. The latter study found that
transfusion was the single factor most reliably
associated with increased risk of postoperative
morbidity
2) Techniques of Blood Conservation
In 2005 we reported our initial experience in 200
Jehovah’s witness patients undergoing cardiac
surgery [12]. Since then , we have had to deal with
the withdrawal of Aprotinin which we thought was
an important weapon in our therapeutic
armentarium. The change of protocol by 1 g at
induction and 1 g at the end of bypass of EACA did
not alter our final results and this change did not
alter in our bleeding control in any way. Fifty years
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prophylactic use of antifibrinolytics for cardiac
surgical patients demonstrate that aprotinin and
EACA reduce postoperative blood loss and
consequently , the requirement for blood
transfusions and reoperation for bleeding compared
to placebo or treatment. Traditionally , evidence in
favor of EACA is not compelling , but in head-to-
head comparisons there is an increased risk of death
among patients receiving aprotinin compared to
those on lysine analog as indicated by the BART
trial. All of these have been demonstrated on huge
series including over 12,000 patients. These
differences did not appear in our two small groups.
The aim of all efforts to reduce the need of allogeneic
blood transfusions is to avoid associated risks. There
should particularly be a favourable effect according to
the rate of transfusion-transmitted virus infections
and immunological side-effects. The acceptance of an
individually adjusted lowest haematocrit level and the
minimisation of intra-operative blood loss by the
application of optimal surgical techniques are among
the most essential strategies to reduce or even avoid
allogeneic blood transfusions
Actively reducing the number of patients requiring
blood transfusion after cardiac surgery is a process
which involves actors at every stage of
hospitalization and, as such, requires more than the
simple minimization of surgical invasiveness once
held to be a key factor [13-15] each detail in the
treatment of these patients is crucial. Starting
preoperatively by raising the level of hemoglobin by
use of EPO and iron therapy, eliminating any
hemodilution, to proper operative field drainage to
reduce the incidence of hematomas related to
various invasive maneuvers over the course of
hospitalization, keeping the hemoglobin value under
15.5 to avoid associated complications with high
hematocrit value [16]. The most recent example of
this comprehensive multimodality approach is the
mini-cardiopulmonary bypass system that we have
been using for the last three years, combined with
retro-priming and a cell saver [16-21] which
maintains a constant hemoglobin level, often low in
cardiac patients. Volume expansion in these patients
is associated with a real risk of hemodilution and
active participation of the anesthetist is essential to
avoid additional iatrogenic vasoplegia, which is
greatly facilitated by concentration-aimed ultra-fast-
track anesthesia protocols [22]. However,
multifactorial progress has been made since the
series published by Cooley [14], which has recently
been confirmed by Jassar [13]. In contrast with
teams who use systemic hypothermia or crystalloidcardioplegia, normothermic surgery provides the
same rheological results without hemodilution. The
complete, unmodified Cornell University protocol
has therefore been systematically employed [6]. This
attitude is all the more important in that
preoperative hemodilution induced by deferred auto-
transfusion cannot be performed upon Jehovah’s
Witnesses who refuse any interruption of the blood
circulation for religious reasons.
3) Legal and Ethical Aspects of Non Transfusion
It has been suggested that patients who receive
transfusions following cardiac surgery had twice the
long-term mortality risk than patients who did not
receive transfusions [4,15]. The administration of
blood transfusions therefore appears to be an
independent factor of death. If these results attain
factual status, then for both medical and legal
reasons, all efforts must be made to avoid recourse
to blood transfusion not only amongst Jehovah’s
Witnesses, but in all patients. A review of the
existing literature on methods of blood transfusion
indicates not only a discordance in practice amongst
medical teams, but even amongst members of the
same team: yet the morbidity-mortality rates are
ubiquitous in the first 30 postoperative days [1,2,23].
Therefore, it appears desirable to replace these highly
unsystematic methods of transfusion with a protocol
of blood conservation which involves all members of
the caring team. To undertake such a protocol is
both medically justified and feasible.
The restraining factor in the implementation of such a
protocol is cost, as the proposed blood conservation
protocol relies upon two medications: aprotinin and
EPO [3,24]. Hence, the cost-benefit analysis depends
primarily on the price of EPO. It must be remembered
that EPO takes effect with some delay, its effectiveness
is uncertain and, at present, its cost is prohibitively
expensive. The extent of the delay in its effectiveness
depends on the degree of preoperative anaemia. In
France, EPO is used in the treatment of anaemia
linked to renal failure, and occasionally preoperatively
in anaemic patients.
The decision not to administer blood transfusions
presents the medical team with an ethical dilemma
as, in extreme circumstances, the members may be
confronted with a situation in which a patient who
could otherwise been saved must be left to die in
order for their choice of non transfusion to be
respected. Not only does this present an ethical
dilemma for doctors but, in France, also presents a
potential legal dilemma, since the preoperative
consent form signed by the patient does not hold
value, in light of the principal of “non-assistance to a
person in danger”, which is in direct opposition to
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of the utmost importance to reduce all possible risks
related to non transfusion [23] in order to prevent the
possibility of extreme situations in which such ethical
and legal dilemmas may arise. We succeeded in this
aspect in all cases except four who were conscious and
repeatedly refused transfusion despite the propositions
of the attending medical professionals. These
preoperative exclusions account for the better results
obtained in group B compared with the outcomes
attained in group A. This rigorous selection process
allowed us to propose standard techniques of
treatment to all our patients, such as mitral valve
repair and total arterial revascularization, a technique
which enhances blood conservation. Redo operations
did not present a problem as we systematically applied
the technique described by O’Bryan which has not
resulted in a single major cardiac event in over 300 re-
operations [20]. Nevertheless, these operative redos
remain risky endeavors which must be evaluated on a
case by case basis.Conclusion
Cardiac surgery without transfusion may be performed
with an equivalent risk to standard surgery. This has
been made possible by the progress in methods of blood
conservation employing pharmacological agents -
namely aprotinin then EACA - and erythropoietin and
improving the physical design of cardio-pulmonary by-
pass techniques. Nevertheless, patient selection remains
extremely important to achieve these results.
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